← Back to Search

Procedure

MorpheusV Applicator for Stress Incontinence

N/A
Waitlist Available
Led By Tracy Blusewicz, MD
Research Sponsored by InMode MD Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 months
Awards & highlights

Study Summary

This study is evaluating whether a new treatment for stress urinary incontinence and vulvovaginal atrophy may be effective.

Eligible Conditions
  • Vulvovaginal Symptoms
  • Stress Incontinence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
An objective change as measured by standardized cough stress test
An objective evaluation of vaginal atrophy/estrogenization
Evaluation of histological changes to vaginal canal tissue
+4 more
Secondary outcome measures
Adverse Events
Discomfort scale
Occurrence of expected post treatment immediate response

Trial Design

1Treatment groups
Experimental Treatment
Group I: MorpheusV Applicator (active)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MorpheusV Applicator
2021
N/A
~50

Find a Location

Who is running the clinical trial?

InMode MD Ltd.Lead Sponsor
23 Previous Clinical Trials
1,324 Total Patients Enrolled
Tracy Blusewicz, MDPrincipal InvestigatorAdvanced Women's Care of the Lowcountry, PC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy
2021. "Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04705571.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top